Cash and Cash Equivalents, at Carrying Value of Unicycive Therapeutics, Inc. from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
Unicycive Therapeutics, Inc. quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • Unicycive Therapeutics, Inc. Cash and Cash Equivalents, at Carrying Value for the quarter ending 30 Sep 2025 was $42,695,000.
Source SEC data
View on sec.gov
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

Unicycive Therapeutics, Inc. Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $42,695,000 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $22,327,000 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $19,769,000 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $26,142,000 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2023 $14,345,000 +$7,335,000 +105% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $18,818,000 +$8,245,000 +78% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $24,332,000 +$10,712,000 +79% 31 Mar 2023 10-Q 16 May 2023 2023 Q1
Q4 2022 $455,000 -$16,124,000 -97% 31 Dec 2022 10-Q 14 Nov 2023 2023 Q3
Q3 2022 $7,010,000 -$11,001,000 -61% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $10,573,000 +$10,572,000 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $13,620,000 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $16,579,000 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $18,011,000 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $1,000* 30 Jun 2021 10-Q 16 Aug 2021 2021 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.